Medicina,
Journal Year:
2022,
Volume and Issue:
59(1), P. 45 - 45
Published: Dec. 27, 2022
Background
and
Objectives:
An
increasing
number
of
studies
have
shown
the
influence
primary
tumor
location
colon
cancer
on
prognosis,
but
prognostic
difference
between
cancers
at
different
locations
remains
controversial.
After
comparing
differences
left-sided
right-sided
cancer,
study
subdivided
into
three
parts,
respectively,
explored
which
parts
had
most
significant
differences,
with
aim
to
further
analyze
significance
cancer.
Materials
Methods:
Clinicopathological
data
patients
who
underwent
radical
surgery
from
Surveillance,
Epidemiology,
End
Results
Program
database
were
analyzed.
The
was
divided
two
groups
(2004–2009
2010–2015)
based
time
intervals.
Two
survival
by
using
Cox
regression
analyses.
verified
in
analyses
after
propensity
score
matching.
Results:
Patients
worse
cancer-specific
overall
compared
Survival
cecum
sigmoid
found
be
among
six
both
2004–2009
2010–2015
periods.
matching,
multivariate
showed
that
an
independent
unfavorable
factor
for
specific
(HR
[95%
CI]:
1.11
[1.04–1.17],
p
=
0.001
2004–2009;
HR
1.23
[1.13–1.33],
<
1.09
[1.04–1.14],
Conclusions:
indicates
prognosis
is
than
colon.
current
dichotomy
model
(right-sided
vs.
colon)
may
inappropriate
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: May 29, 2024
Abstract
Right-sided
colon
cancer
(RCC)
and
left-sided
(LCC)
differ
in
features
outcomes
because
of
variations
embryology,
epidemiology,
pathology,
prognosis.
This
study
sought
to
identify
significant
factors
impacting
patient
survival
through
Bayesian
modelling.
Data
was
retrospectively
analysed
from
a
colorectal
neoplasia
database.
on
demographics,
perioperative
risks,
treatment,
mortality,
patients
who
underwent
surgery
January
2010
December
2021.
involved
2475
patients,
with
58.7%
having
RCC
41.3%
LCC.
had
notably
higher
mortality
rate,
their
overall
(OS)
rates
were
slightly
lower
than
those
LCC
(P
<
0.05).
stages
I–IV
consistently
exhibited
worse
OS
relapse-free
(RFS)
Factors
like
age,
BMI,
ASA
score,
stage,
comorbidities
associations
RFS.
Poor
moderate
differentiation,
lymph
node
yield,
organ
resection
linked
while
receiving
chemotherapy;
BMI
levels
elective
associated
better
(all
P
Our
reveals
key
differences
between
LCC,
emphasising
the
impact
survival.
These
findings
could
inform
personalised
treatment
strategies
for
patients.
Translational Cancer Research,
Journal Year:
2024,
Volume and Issue:
13(1), P. 371 - 380
Published: Jan. 1, 2024
Background:
Colorectal
cancer
(CRC)
ranks
highly
in
malignant
tumor
incidence
and
mortality
rates,
severely
affecting
human
health.
The
predictive
value
of
the
systemic
immune-inflammation
index
(SII)
CRC
prognosis
is
gaining
attention,
but
there
limited
research
on
combined
preoperative
postoperative
SII.
This
study
aims
to
explore
prognostic
SII
disease-free
survival
(DFS)
patients
undergoing
radical
surgery
for
rectal
cancer.
Methods:
We
enrolled
292
with
who
underwent
resection
at
Affiliated
Hospital
Xuzhou
Medical
University
from
May
2018
September
2020,
along
regular
follow-ups
document
DFS.
Patients'
complete
blood
cell
counts
were
assessed
before
between
21–56
days
postoperatively.
Calculating
SII,
categorized
into
four
groups
based
optimal
cutoff
values:
(I)
low-low
group
(preoperative
<449.325
<568.13);
(II)
high-low
≥449.325
(III)
low-high
≥568.13);
(IV)
high-high
≥568.13).
receiver
operating
characteristic
(ROC)
curve
analysis
evaluated
prediction
efficacy
preoperative,
postoperative,
Kaplan-Meier
generated
DFS
curves,
Cox
regression
determined
factors.
Results:
With
a
median
follow-up
41
months,
65.4%
(191/292)
reached
clinical
pathological
features
are
balanced
comparable
(P>0.05).
area
under
ROC
was
0.668
[95%
confidence
interval
(CI):
0.6–0.737],
0.696
(95%CI:
0.63–0.763),
0.741
(95%
CI:
0.681–0.802),
respectively.
After
adjusting
confounding
factors
such
as
adjuvant
therapy,
differentiation,
vascular
invasion,
neural
tumor-node-metastasis
(TNM)
stage,
carcinoembryonic
antigen
(CEA),
carbohydrate
19-9
(CA19-9),
significant
differences
observed
[hazard
ratio
(HR)
=2.403;
95%
1.255–4.602;
P=0.008],
(HR
=5.058;
2.389–10.71;
P<0.001),
=6.214;
3.474–11.115;
P<0.001)
compared
group,
higher
risks
adverse
outcomes.
Conclusions:
Combined
has
better
than
monitoring
or
alone
surgery.
Journal of the Anus Rectum and Colon,
Journal Year:
2025,
Volume and Issue:
9(1), P. 134 - 144
Published: Jan. 24, 2025
To
clarify
the
risk
factors
affecting
prognosis
after
primary
tumor
resection
(PTR)
in
patients
with
metastatic
colorectal
cancer
synchronous
peritoneal
metastasis
(mCRC-SPM).
Patients
were
enrolled
prospectively
JSCCR
project
"Grading
of
Peritoneal
Seeding
Colorectal
Cancer."
Factors
that
may
influence
overall
survival-age,
sex,
location
tumor,
lymph
node
metastasis,
presence
liver
degree
index
(PCI),
cure,
and
postoperative
chemotherapy-in
PTR
group
examined
using
multivariate
analysis.
Of
133
mCRC-SPM,
112
underwent
PTR.
Among
them,
26
(23.2%)
had
mCRC-SPM
grade
P1,
47
(42.0%)
P2,
39
(34.8%)
P3.
The
median
PCI
was
4
(range,
1-28);
no
surgery-related
deaths
occurred.
Postoperative
complications
Clavien-Dindo
classification
≥grade
2
observed
20
(17.9%)
patients.
R0
surgery
became
more
difficult
as
dissemination
increased,
a
significantly
better
than
non-PTR
group.
In
analysis,
age
≥75
years,
rectal
cancer,
higher
PCI,
non-curative
resection,
non-treatment
systemic
chemotherapy
associated
poor
are
infrequent
for
P1
localized
dissemination,
be
considered
aggressive
treatment.
including
increased
reduced
survival
benefit
from
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: May 1, 2025
Immunotherapy
has
become
the
first-line
treatment
for
metastatic
mismatch
repair
deficient
(dMMR)
colorectal
cancer.
The
efficacy
and
safety
of
neoadjuvant
immunotherapy
non-metastatic
dMMR
cancer
remain
unclear.
In
this
article,
we
explore
clinical
effect
We
collected
data
from
databases
(PubMed,
Wanfang
Embase,
Cochrane
Library,
China
National
Knowledge
Infrastructure
databases)
up
to
November
2024.
primary
outcomes
major
pathological
response
(MPR),
complete
(pCR),
other
were
analyzed
final
results.
secondary
(pCR
rates
subgroups)
also
analyzed.
included
21
articles
with
628
cancers.
A
pCR
was
found
in
320/480
(66.6%)
patients
[effect
size
(ES):
0.70,
95%
CI:
0.66
0.74]
fixed-effects
model
little
heterogeneity.
MPR
388/452
(85.8%)
(ES:
0.86,
0.81
0.91)
subgroup
analysis,
similar
T1-T3
group
T4a-T4b
minimal
heterogeneity
(OR:
0.76,
0.48
1.22).
colon
rectal
1.41,
0.39
5.12).
Similar
immune
monotherapy
therapy
plus
chemotherapy
0.74,
0.26
2.10)
Neoadjuvant
achieves
high
For
locally
advanced
T4
stage
cancer,
can
still
achieve
good
rates.
pCRs
rates,
avoiding
toxic
side
effects
caused
by
combined
dual
chemo(radio)therapy.
could
be
another
option
https://www.crd.york.ac.uk/prospero/,
identifier
CRD42024594173.
Aging,
Journal Year:
2023,
Volume and Issue:
15(14), P. 7098 - 7123
Published: July 21, 2023
In
this
study,
we
compared
the
prognosis,
tumor
immune
microenvironment
(TIM),
and
drug
treatment
response
between
left-sided
(LCC)
right-sided
(RCC)
colon
cancer
to
predict
outcomes
in
patients
with
LCC
RCC.Based
on
identified
differentially
expressed
genes
using
single-cell
RNA
sequencing
data,
constructed
validated
a
prognostic
model
for
RCC
TCGA-COAD
cohort
GSE103479
cohort.
Moreover,
differences
of
TIM
characteristics
patients.We
five-gene
four-gene
patients,
both
showed
excellent
performance.
The
higher
risk
scores
were
significantly
associated
greater
metastasis
(P
=
2.6×10-5),
N
stage
0.012),
advanced
pathological
1.4×10-4),
more
stable
microsatellite
status
0.007)
but
not
T
0.200).
For
>
0.05).
Additionally,
infiltration
by
CD8
regulatory
cells
M0,
M1,
M2
macrophages
differed
<
APC
TP53
mutations
common
contrast,
KRAS,
SYNE1,
MUC16
addition,
mutation
burden
values
than
5.9×10-8).
expression
checkpoint
targets
was
0.05),
indicating
that
maybe
sensitive
immunotherapy.
However,
did
differ
their
sensitivity
eight
selected
chemicals
or
target
drugs
average
half-maximal
inhibitory
concentrations
camptothecin,
teniposide,
vinorelbine,
mitoxantrone
lower
low-risk
high-risk
score
they
these
four
drugs.We
investigated
TIM,
which
may
contribute
accurate
prognosis
cancer.
International Journal of Medical Sciences,
Journal Year:
2024,
Volume and Issue:
21(10), P. 1824 - 1839
Published: Jan. 1, 2024
Colorectal
cancer
is
a
heterogeneous
disease
which
can
be
divided
into
proximal
colon
cancer,
distal
and
rectal
according
to
the
anatomical
location
of
tumor.Each
colorectal
exhibits
distinct
characteristics
in
terms
incidence,
clinical
manifestations,
molecular
phenotypes,
treatment,
prognosis.Notably,
differs
significantly
from
cancers
other
subsites.An
increasing
number
studies
have
highlighted
presence
unique
tumor
biological
cancer.Gaining
deeper
understanding
these
will
facilitate
accurate
diagnosis
treatment
approaches.
